# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Ritu Baral upgrades Spero Therapeutics (NASDAQ:SPRO) from Hold to Buy.
Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:SPRO) with a Overweight.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $7 p...
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $7 p...
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of ...
Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:SPRO) with a Overweight.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:SPRO) with a Buy and maintains $7 p...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...